Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080531 · ClinicalTrials.gov registry record · Phase 4
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 165
- Enrollment target
NCT04080531: Completed Phase 4 study, sponsored by Emory University.
NCT04080531 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 165 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04080531, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 165 participants
- Enrollment target
Study Summary
This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.
Primary Outcome
HAI in blood at week 21 for all variants
Interventions
- BIOLOGICAL Pneumococcal 13-valent Conjugate Vaccine
- BIOLOGICAL Trivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 4 |
What the finished NCT04080531 record still lists
NCT04080531 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Pneumococcal 13-valent Conjugate Vaccine is the first listed.
NCT04080531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04080531 about?
NCT04080531 is a clinical study titled "Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders". This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' ...
What is the current status of trial NCT04080531?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 165 participants. The study started on 2019-10-18. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT04080531?
The interventions under investigation include: Pneumococcal 13-valent Conjugate Vaccine (BIOLOGICAL), Trivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04080531?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04080531's enrollment target sits among peer trials
165 492nd of 2000 higher than 1,505 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI